# US 2008/0279846 A1 · Methods of treatment and prevention of neurodegenerative diseases and disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0279846 A1
- Document ID: US20080279846A1
- Status: Published application
- Kind: A1
- Application number: 12/118,973
- Filed: 2008-05-12
- Published: 2008-11-13
- Earliest claimed: 2007-05-11
- Assignees: Thomas Jefferson University; University of Medicine and Dentistry of New Jersey
- Inventors: Yi SHI; Robert NAGELE
- Web page: https://patentgrep.com/patent/US20080279846A1

## CPC

- C07D 239/38: One sulfur atom
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 25/00: Drugs for disorders of the nervous system
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides compostions and methods useful for treating and preventing neurodegenerative disease and neurologically related disorders by inhibition of Lp-PLA2. The compositions and methods are useful for treating and preventing diseases and disorders with abnormal blood brain barrier (BBB) function, for example neurodegenerative diseases with a permeable BBB, such as but not limited to, Alzheimer's Disease, Huntington's Disease, Parkinson's Disease and Vascular Dementia.

## Claims

### Claim 1

A method of treating and/or preventing a neurodegenerative disorder or disease in a subject, the method comprising identifying a subject with, or at risk of developing a neurodegenerative disease or disorder and administering to the subject in need thereof a pharmaceutical composition comprising an agent that inhibits the activity and/or expression of the Lp-PLA2 protein.

### Claim 2 (depends on 1)

The method of claim 1, wherein the neurodegenerative disease or disorder is selected from a group consisting of: Alzheimer's Disease, Vascular Dementia, Parkinson's Disease and Huntington's Disease.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject is human.

### Claim 4

A method of treating and/or preventing a subject with or at risk of vascular dementia comprising identifying a subject with, or at risk of developing a vascular dementia and administering to a subject in need of a pharmaceutical composition comprising an agent which inhibits the activity and/or expression of Lp-PLA2 protein, wherein inhibition of the Lp-PLA2 protein reduces or stops a symptom of vascular dementia.

### Claim 5 (depends on 4)

The method of claim 4, wherein the vascular dementia is associated with Alzheimer's disease.

### Claim 6

A method of treating and/or preventing a disease or disorder associated with an abnormal blood brain barrier in a subject, comprising identifying a subject with, or at risk of an abnormal blood brain barrier, and administering to the subject in need of a pharmaceutical composition comprising an agent which inhibits the expression and/or activity of the Lp-PLA2 protein.

### Claim 7 (depends on 6)

The method of claim 6, wherein the abnormal BBB is a permeable blood brain barrier.

### Claim 8 (depends on 6)

The method of claim 6, wherein the disease or disorder is a neurodegenerative disease or disorder.

### Claim 9 (depends on 6)

The method of claim 6, wherein the disease or disorder is vascular dementia.

### Claim 10 (depends on 8)

The method of claim 8, wherein the neurodegenerative disease or disorder is Alzheimer's disease.

### Claim 11 (depends on 8)

The method of claim 8, wherein the neurodegenerative disease or disorder is selected from a group consisting of: Alzheimer's disease, Vascular dementia, Parkinson's Disease and Huntington's Disease.

### Claim 12

A method of decreasing beta amyloid accumulation in the brain of a subject, comprising identifying a subject with, or at risk of beta amyloid accumulation in the brain and administering to the subject in need of a pharmaceutical composition comprising an agent which inhibits the expression and/or activity of Lp-PLA2 protein, wherein inhibition of the Lp-PLA2 protein reduces or stops a symptom of beta amyloid accumulation in the brain.

### Claim 13 (depends on 12)

The method of claim 12, wherein the beta amyloid is Abetal-42.

### Claim 14

A method of treating and/or preventing Alzheimer's Disease in a subject in need thereof, comprising:
(i) screening the subject for likelihood of having or developing Alzheimers Disease,
(ii) administering to the subject a pharmaceutical composition comprising an agent which inhibits the expression and/or activity of Lp-PLA2 protein, wherein inhibition of the Lp-PLA2 protein reduced a symptom of Alzheimer's Disease, wherein the subject is identified to have an increased risk or likelihood of developing Alzheimer's Disease determined by step (i).

### Claim 15

A method for preventing or reducing the risk of developing Alzheimer's disease, the method comprising assessing the risk of a subject developing Alzheimer's disease, wherein a clinical directs the subject to be treated with an agent which inhibits the expression and/or activity of Lp-PLA2 protein if the subject is at risk of developing Alzheimer's Disease.

### Claim 16 (depends on 1, 4, 6, 12, 14, 15)

The method of claims 1, 4, 6, 12, 14 or 15 wherein the agent is a small molecule, nucleic acid, nucleic acid analogue, protein, antibody, peptide, aptamer or variants or fragments thereof.

### Claim 17 (depends on 16)

The method of claim 16, wherein the nucleic acid agent is an RNAi agent.

### Claim 18 (depends on 16)

The method of claim 16, wherein the RNAi agent is a siRNA, shRNA, miRNA, dsRNA or ribozyme or variants thereof.

### Claim 19 (depends on 16)

The method of claim 16, wherein the small molecule is 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)-aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or SB480848 or a salt thereof.

### Claim 20 (depends on 16)

The method of claim 16, wherein the small molecule is N-(2-diethylaminoethyl)-2-[2-(2-(2,3-difluorophenyl)ethyl)-4-oxo-4,5,6,7-tetrahydro-cyclopentapyrimidin-1-yl]-N-(4′-trifluoromethyl-biphenyl-4-ylmethyl)acetamide or a salt thereof.

### Claim 21 (depends on 16)

The method of claim 16, wherein the small molecule is N-(1-(2-Methoxyethyl)piperidin-4-yl)-2-[2-(2,3-difluorobenzylthio)-4-oxo-4H-quinolin-1-yl]-N-(4′-trifluoromethylbiphenyl-4-ylmethyl)acetamide; or a salt thereof.

### Claim 22 (depends on 16)

The method of claim 16, wherein the small molecule is methyl 2-[4-({[2-[2-(2,3-difluorophenyl)ethyl]-4-oxopyrido[2,3-d]pyrimidin-1(4H)-yl]acetyl}{[4′-(trifluoromethyl)-4-biphenylyl]methyl}amino)-1-piperidinyl]-2-methylpropanoate or a salt thereof.

### Claim 23 (depends on 1, 4, 6, 12, 14, 15)

The method of claims 1, 4, 6, 12, 14 or 15, further comprising assessing cognitive function of said subject after administration of the pharmaceutical composition comprising agents that inhibit Lp-PLA2.

### Claim 24 (depends on 1, 4, 6, 12, 14, 15)

The method of claims 1, 4, 6, 12, 14 or 15, further comprising monitoring treatment by assessing cerebral blood flow or blood-brain barrier function.

### Claim 25 (depends on 1, 4, 6, 12, 14, 15)

The method of claims 1, 4, 6, 12, 14 or 15, further comprising administering to the subject additional therapeutic agents.

### Claim 26 (depends on 25)

The method of claim 25, wherein additional therapeutic agents are ARICEPT or donepezil, COGNEX or tacrine, EXELON or rivastigmine, REMINYL or galantamine, anti-amyloid vaccine, Abeta-lowering therapies, mental exercise or stimulation.

### Claim 27 (depends on 1, 4, 6, 12, 14, 15)

The method of claims 1, 4, 6, 12, 14 or 15, wherein the subject is mammalian.

### Claim 28 (depends on 4)

The method of claim 4, wherein the subject is human.

### Claim 29 (depends on 6)

The method of claim 6, wherein the subject is human.

### Claim 30 (depends on 12)

The method of claim 12, wherein the subject is human.

### Claim 31 (depends on 14, 15)

The method of claims 14 or 15, wherein the subject is human.

### Claim 32 (depends on 27)

The method of claim 27, wherein the mammalian is a human.

### Claim 33

Use of an agent which inhibits the expression and/or activity of Lp-PLA2 protein for the preparation of a medicant for treatment and/or prevention of a neurodegenerative disease or disorder.
